Francesco Franchi, MD
Cardiovascular Disease · Jacksonville, FLNPI 1588034995
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,376 of the $10,376 with a category attached, or 100.0%. AstraZeneca accounts for 82.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $4,833 and has fallen 89.7% since, to $500 in 2025.
Across 15 payments — averaging $691.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Sanofi-aventis U.S. LLC$1K
- Accriva Diagnostics Inc.$500
Across 92 payments — averaging $16,743 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$966K
- Amgen$201K
- American Regent$165K
- AstraZeneca$88K
- Boehringer Ingelheim$59K
- Boehringer Ingelheim Pharma GmbH & Co.kg$35K
- plus $26K from 1 others
What the payments were for
- Consulting fees$10,376100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $8,592 |
| Sanofi-aventis U.S. LLC | 1 | $1,284 |
| Accriva Diagnostics Inc. | 1 | $500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,376 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $8,861 |
| Atorvastatin Calcium | 26 | $126 |
| Losartan Potassium | 26 | $111 |
| ClopidogrelClopidogrel Bisulfate | 11 | $97 |
| Carvedilol | 21 | $77 |
| Spironolactone | 19 | $64 |
| Furosemide | 15 | $58 |
| Amlodipine Besylate | 13 | $24 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Jacksonville
- Alan MillerJacksonville$547K
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.